Blogger

Background: A Bush double-cross on HIV travel ban Tuesday, November 20, 2007 The Bush administration is trying to pull a fast one rushing through draconian proposed new regulations that will restrict even further the entry of HIV-positive people into to the US, just one year after having promised to ease them. By Doug Ireland The […]

worked with Dr Scally in the past and he is one of the country’s experts on anabolic research. This is an e-book he just published. America’s Nuremberg – Human Experimentation in Anabolic Steroid Research by Michael Scally MD (eBook) “America’s Nuremberg – Human Experimentation in Anabolic Steroid Research” is a discussion of the ethical, medical,

WHEN: OCT 24, 6:30 PM WHERE: UNITED WAY AT 50 WAUGH DRIVE SPEAKER: NELSON VERGEL (POWERUSA.ORG) LIMITED SEATING. E-mail [email protected] or call the Houston Buyers Club at 713/520-5288 TOPICS: 1- Review of data on two new drugs in two new class recently approved- Selsentry- CCR5 inhibitor (https://www.selzentry.com/) and Isentress – integrase inhibitor(https://www.isentress.com ) 2- Review

Merck Gets FDA ApprovalFor New HIV Treatment Wall St JnlBy JENNIFER CORBETT DOORENOctober 12, 2007 5:50 p.m. WASHINGTON — A U.S. Food and Drug Administration panel Friday approved a new type of HIV drug from Merck & Co., a company spokeswoman said. The drug, known by the brand name Isentress, was approved for use in

Merck’s New AIDS Drug Has Promise — if It Isn’t Too Pricey Wall St JournalBy SARAH RUBENSTEINOctober 11, 2007; Page B1 Merck & Co. could break new ground on the AIDS-fighting front this week with the Food and Drug Administration’s expected approval of Isentress, a new type of drug that could be especially useful for

Still slow response (60 responders in a list of 2500 people in pozhealth at yahoogroups.com), but we are starting to see some valuable information Click on “view” in questions 2, 3 and 4 to see what people have typed in https://www.surveymonkey.com/sr.aspx?sm=rc8hHUnWoT5VVui7aS9Q_2fsfxahbyw7goBCGlfANmm4A_3d For those of you who want to share with us, use this link https://www.surveymonkey.com/s.aspx?sm=dIXsY8YIuuh5f_2fMLZasLgA_3d_3d

May 8, 2007 Dear ADAP Director: As you may be aware, your HIV patients will soon face an abrupt change in available treatment options for HIV-related weight loss and AIDS wasting syndrome. In March 2007, Watson Laboratories, the sole manufacturer of the inexpensive HIV anti-wasting agent nandrolone decanoate (also known as Deca-Durabolin), halted production of

Tuesday, October 09, 2007 African countries should follow Thailand’s lead in manufacturing their own affordable medication in the face of U.S. pressure. By Lara Santoro October 9, 2007 In January, the Thai government gave its domestic drug manufacturers carte blanche to effectively copy the formula for Abbot Laboratories’ AIDS drug, Kaletra, and reproduce it in

Lipodystrophy Update- PoWeR Health Solutions Newsletter- Issue 1

CCR5 Antagonists (Maraviroc and Vicriviroc) CCR5 antagonists block viral binding to the CCR5 chemokine coreceptor. Several CCR5 antagonists have been tested in clinical trials. In August 2007, maraviroc was approved for use in multidrug-resistant patients with R5-only virus. A phase IIb/III trial of this agent in treatment-experienced patients has been reported.[4,5] A phase IIb/III study

The Georgetown University Health Policy Institute has written A CONSUMER GUIDE FOR GETTING AND KEEPING HEALTH INSURANCE for each state and the District of Columbia — fifty-one in all. These Consumer Guides are available at this web site and will be updated periodically as changes in federal and state policy warrant. https://healthinsuranceinfo.net/ I hear this